Leslie Sloan, PhD

Leslie Sloan is the CEO of OmniNano Pharmaceuticals and a seasoned global executive with a proven track record leading organizations, building high-performing cross-functional teams, and driving successful execution of drug development programs. Dr. Sloan has led efforts across multiple therapeutic areas, including rare diseases, oncology, and cardiovascular, as well as various modalities such as small molecules, peptides, and biologics.

Her expertise and experience span executive strategy to operational leadership, culminating in multiple successful BLA and NDA submissions. Dr. Sloan has played a key role in the regulatory approvals of several high-impact therapies, including Loargys® (pegzilarginase), Somatuline® Depot (lanreotide), Dysport® (abotulinumtoxinA), and XERMELO® (telotristat ethyl).

Leslie holds PhD and MS degrees in Bioorganic Chemistry from Yale University and a BS in Chemistry and Medical Biology from Southeastern Oklahoma State University.